The ESMO Congress 2024 in Barcelona provided the occasion to disseminate the latest cancer research and provide high-quality education for oncologists from all over the world.
Annals of Oncology, along with The New England Journal of Medicine, Nature Medicine, JAMA Dermatology and The Lancet published twenty-eight articles concomitantly with the congress.
Below is a list of the thirteen articles published in Annals of Oncology, showcasing the journal's pivotal role in driving innovation in the field of oncology.
- ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
- Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
- Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase 3 KEYNOTE-006 study
- Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies
- A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxteca: ERICA study (WJOG1432oB)
- Subcutaneous versus intravenous nivolumab for renal cell carcinoma
- How AI will transform cancer care
- Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial
- Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
- The global epidemic of early-onset cancer: Nature, nurture, or both?
- Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
- First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration
- Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer